Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 11:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33,175 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Safety Clear all
Completed Phase 2 Interventional

Study to Assess the Safety, Tolerance and Efficacy of Tezampanel in Patients With Acute Migraine

NCT00567086
View directory record Official record
Conditions
Migraine
Interventions
TEZAMPANEL
Drug
Lead sponsor
TorreyPines Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2007 · Synced Sep 5, 2026, 11:15 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06589986
View directory record Official record
Conditions
Moderately to Severely Active Ulcerative Colitis
Interventions
Afimkibart, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
58
States / cities
Dothan, Alabama • Lancaster, California • Orange, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 5, 2026, 11:15 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies

NCT02906670
View directory record Official record
Conditions
Oncology
Interventions
Sym013
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Sep 5, 2026, 11:15 PM EDT
Active, not recruiting Phase 3 Interventional

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

NCT05973773
View directory record Official record
Conditions
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Interventions
TAS6417
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Henderson, Nevada • Las Vegas, Nevada • Canton, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 5, 2026, 11:15 PM EDT
Enrolling by invitation Not applicable Interventional

Helping Cancer Patients Manage Neuropathy Symptoms From Chemotherapy With a Low-Intensity, Low-Risk Cranial PEMF Device

NCT07061769
View directory record Official record
Conditions
Chemotherapy Induced Peripheral Neuropathy, Chemotherapy Induced Peripheral Neuropathy (CIPN), Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Neuropathic Pain
Interventions
SHIFT
Device
Lead sponsor
FluxWear, INC
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Sep 5, 2026, 11:15 PM EDT
Completed Phase 2 Interventional Results available

48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection

NCT00089583
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I
Interventions
LEXIVA (GW433908), Ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
2 Years to 18 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 5, 2026, 11:15 PM EDT
Completed Not applicable Interventional Results available

The HERCULES Trial - A Safety and Effectiveness Study of the Herculink Elite Renal Stent to Treat Renal Artery Stenosis

NCT00490841
View directory record Official record
Conditions
Renal Artery Obstruction, Hypertension, Renal
Interventions
Herculink Elite Renal Stent System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Sep 5, 2026, 11:15 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety Study of Gintuit™ in Subjects Requiring Socket Grafting

NCT01929954
View directory record Official record
Conditions
Edentulous Alveolar Ridge
Interventions
Gintuit, Bio-Gide
Biological · Device
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Sep 5, 2026, 11:15 PM EDT
Completed Not applicable Interventional

A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients

NCT00002354
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Stavudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Whitehouse Station, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 5, 2026, 11:15 PM EDT
Withdrawn Not applicable Interventional

First-in-Human Safety Study Of Laser Tissue Welding For Surtureless Laparoscopic Partial Nephrectomy

NCT02061605
View directory record Official record
Conditions
Benign Renal Tumors, Malignant Renal Tumors
Interventions
Laser Tissue Welding Device
Device
Lead sponsor
Laser Tissue Welding, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Sep 5, 2026, 11:15 PM EDT
Completed No phase listed Observational

An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)

NCT01009905
View directory record Official record
Conditions
Growth Hormone Disorder, Pituitary Dwarfism, Hypopituitarism
Interventions
somatropin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Up to 18 Years
Enrollment
22,960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 5, 2026, 11:15 PM EDT
Completed Phase 1 Interventional Results available

Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients

NCT02530905
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
SRP-4045, Placebo
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
7 Years to 21 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 5, 2026, 11:15 PM EDT
Recruiting Phase 1 Interventional

Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders

NCT06672705
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Epcoritamab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
Timothy Voorhees
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Sep 5, 2026, 11:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Diindolylmethane in Preventing Cancer in Healthy Volunteers

NCT00784394
View directory record Official record
Conditions
Healthy, no Evidence of Disease
Interventions
diindolylmethane, placebo, pharmacological study, laboratory biomarker analysis, quality-of-life assessment
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 5, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)

NCT00280566
View directory record Official record
Conditions
Bipolar Mania, Bipolar Disorder
Interventions
Placebo, Ziprasidone Oral Capsule
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
73
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Sep 5, 2026, 11:15 PM EDT
Terminated Phase 2 Interventional Results available

Safety of FMT: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection

NCT02403622
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Fecal Microbiota Preparation
Drug
Lead sponsor
Microbiome Health Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Naperville, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2021 · Synced Sep 5, 2026, 11:15 PM EDT
Terminated Phase 2 Interventional Results available

Org 24448 to Treat Major Depression

NCT00113022
View directory record Official record
Conditions
Depression
Interventions
Org 24448, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
21 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Sep 5, 2026, 11:15 PM EDT
Completed Not applicable Interventional

Viveve Geneveve Treatment of the Vaginal Introitus to Evaluate Safety and Efficacy

NCT03479229
View directory record Official record
Conditions
Female Sexual Dysfunction
Interventions
Geneveve Treatment, Sham Treatment
Device
Lead sponsor
Viveve Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
19
States / cities
La Mesa, California • Orange, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Sep 5, 2026, 11:15 PM EDT
Not listed Phase 3 Interventional

Safety and Efficacy Study of Lithium in Bipolar Disorder

NCT00422331
View directory record Official record
Conditions
Bipolar Disorder, Mania
Interventions
Lithium Carbonate Capsule
Drug
Lead sponsor
JDS Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2007 · Synced Sep 5, 2026, 11:15 PM EDT
Not listed Phase 2 Interventional

Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

NCT01273337
View directory record Official record
Conditions
Stroke, Ischemic Stroke, Stroke in Middle Cerebral Artery (MCA)
Interventions
ALD-401, Sham Procedure
Biological · Procedure
Lead sponsor
Aldagen
Industry
Eligibility
30 Years to 83 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
Los Angeles, California • Miami, Florida • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Sep 5, 2026, 11:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

NCT00000745
View directory record Official record
Conditions
HIV Infections
Interventions
Hepatitis B Vaccine (Recombinant), gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1991
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 5, 2026, 11:15 PM EDT
Terminated Phase 1 Interventional

Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer

NCT00783172
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Opioid Growth Factor (OGF)
Drug · Biological
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Allentown, Pennsylvania • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 5, 2026, 11:15 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

NCT02006472
View directory record Official record
Conditions
Huntington's Disease
Interventions
Pridopidine, Placebo
Drug · Other
Lead sponsor
Prilenia
Industry
Eligibility
21 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • Englewood, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Sep 5, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 5, 2026, 11:15 PM EDT